Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment
By Ben Glickman
Ligand Pharmaceuticals said its treatment for molluscum, a viral skin infection, had received approval from U.S. regulators.
The company said Friday that the U.S. Food and Drug Administration had approved Zelsuvmi, a topical prescription medication, to treat moluscum in adults and children one year old or older.
Ligand expects the treatment to be available in the U.S. in the second half of 2024.
The company said the FDA had approved Zelsuvmi as the first novel drug to treat mollescum infections.
Molluscum is a contagious skin infection which can cause lesions. It primarily affects children.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 05, 2024 17:25 ET (22:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities